ArticleInternational journal of women's health2025
Impact of Subchorionic Hematoma on Pregnancy Outcomes in Obstetric Antiphospholipid Syndrome.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LAMB1 regulates COL3A1 and RAC1 expression during subchorionic hemorrhage progression.BMC biology · 2026Article
- A Case of Large Subchorionic Hematoma.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the effects of subchorionic hematoma (SCH) in patients with obstetric antiphospholipid syndrome (OAPS) on pregnancy outcomes, as well as the clinical value of anticoagulant therapy. Methods: This retrospective study included 109 OAPS patients treated at the Fourth Hospital of Shijiazhuang from December 2019 to December 2021. Patients were divided into two groups: SCH group (n=40) and non-SCH group (n=69). Baseline data, laboratory indicators (anti-β2GP I, lupus anticoagulant, ACL, D-D, AA, ADP, ATIII, PS, and PC), complications, and pregnancy outcomes were compared between the groups. Results: There were no significant differences between the two groups concerning the abortion rate, live birth rate (all P>0.05). However, we reported a significantly higher rate of preterm delivery occurring between 34-37 in the SCH group (13.7% vs 1.7%, P=0.027). The proportion of patients with triple-positive antiphospholipid antibodies (aPLs) was significantly higher in the SCH group compared to the non-SCH group (7.5% vs 0.0%, P=0.047). During pregnancy but before routine first-trimester therapy was initiated, the levels of β2GP I, LA, ACL, D-D, AA, and ADP in the SCH group were higher than those in the non-SCH group, while ATIII, PS, and PC levels were lower (all P < 0.05). After treatment, the levels of β2GP I, LA, ACL, D-D, AA, and ADP decreased in both groups compared to their pre-treatment levels (all P < 0.05); however, the levels of D-D and PS in the SCH group remained higher than those in the non-SCH group (all P < 0.05). Conclusion: In patients with OAPS who present with SCH during pregnancy, laboratory indicators suggest more severe immune disorders and coagulopathy, as well as an increased risk of preterm delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.